Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Jul 1998

Kwiatkowski D J, Harpole D H, Godleski J, Herndon J E, Shieh D B, Richards W, Blanco R, Xu H J, Strauss G M, Sugarbaker D J

Abstract excerpt

PURPOSE: To retrospectively construct a comprehensive multivariate model of cancer recurrence and to design a molecular pathologic substaging system in stage I non-small-cell lung cancer (NSCLC). METHODS: All patients with stage I NSCLC resected at Brigham and Women's Hospital (Boston, MA) between 1984 and 1992 with adequate clinical follow-up were studied. The importance of three demographic characteristics,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA Primers

Share to Genes, ras

Share to Lung Neoplasms

Share to Mutation

Share to Neoplasm Staging

Share to Prognosis

Source

Identifiers

PMID: 9667266
DOI: 10.1200/JCO.1998.16.7.2468

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications.PMID 9667266Read ↗

Post-recurrence survival analysis of stage I non-small-cell lung cancer.Semantic proximity Read ↗

Prediction of Recurrence-Free Survival in Postoperative Non–Small Cell Lung Cancer Patients by Using an Integrated Model of Clinical Information and Gene ExpressionSemantic proximity Read ↗

Molecular pathogenesis of early-stage non-small cell lung cancer and a proposal for tissue banking to facilitate identification of new biomarkers.Semantic proximity Read ↗

A molecule based nomogram optimized the prediction of relapse in stage I NSCLCSemantic proximity Read ↗

A biologic risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with the use of ten molecular markersSemantic proximity Read ↗

The possibility of mutations of RAS signaling genes and/or TP53 in combination as a negative prognostic impact on pathological stage I non-small cell lung cancer.Semantic proximity Read ↗

Genetic variations in epigenetic genes are predictors of recurrence in stage I or II non-small cell lung cancer patients.Semantic proximity Read ↗

Prognostic implication of EGFR gene mutations and histological classification in patients with resected stage I lung adenocarcinoma.Semantic proximity Read ↗

Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy.Semantic proximity Read ↗

Risk Factors for Recurrence of Stage I Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma.Semantic proximity Read ↗

Matrix Metallopeptidase-Gene Signature Predicts Stage I Lung Adenocarcinoma Survival Outcomes.Semantic proximity Read ↗

Prognostic Factors for Survival After Recurrence in Patients With Completely Resected Lung Adenocarcinoma: Important Roles of Epidermal Growth Factor Receptor Mutation Status and the Current Staging System.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.